Post Menopausal Osteoporosis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2016, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 5, 1, 1 and 6 respectively for Post Menopausal Osteoporosis.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Post Menopausal Osteoporosis Overview 7
Therapeutics Development 8
Pipeline Products for Post Menopausal Osteoporosis - Overview 8
Post Menopausal Osteoporosis - Therapeutics under Development by Companies 9
Post Menopausal Osteoporosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Post Menopausal Osteoporosis - Products under Development by Companies 13
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
BiologicsMD, Inc. 15
Eli Lilly and Company 16
Enteris BioPharma, Inc. 17
Intas Pharmaceuticals Ltd. 18
Ipsen S.A. 19
Ligand Pharmaceuticals, Inc. 20
NIBEC 21
Oncobiologics, Inc. 22
Paras Biopharmaceuticals Finland Oy 23
Post Menopausal Osteoporosis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
abaloparatide - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
blosozumab - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
BMD-1111 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
calcitonin - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
denosumab - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
denosumab biosimilar - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
denosumab biosimilar - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Drugs for Postmenopausal Osteoporosis - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
lasofoxifene tartrate - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
romosozumab - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
teriparatide biosimilar - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
teriparatide biosimilar - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Post Menopausal Osteoporosis - Dormant Projects 69
Post Menopausal Osteoporosis - Discontinued Products 70
Post Menopausal Osteoporosis - Product Development Milestones 71
Featured News & Press Releases 71
Sep 26, 2016: Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab 71
Sep 19, 2016: Radius Presents Abaloparatide Transdermal Patch Development Program at American Society for Bone and Mineral Research 2016 Annual Meeting 72
Sep 18, 2016: Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR 72
Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis 73
Sep 14, 2016: Amgen to present romosozumab at Investor Call 75
Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting 75
Aug 16, 2016: JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis 77
Jul 21, 2016: Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA 77
Jul 20, 2016: Radius Health Announces Multiple Presentations at the American Society for Bone and Mineral Research 2016 Annual Meeting September 16-19, 2016 78
Jun 08, 2016: UCB presents Phase 3 data from the STRUCTURE study of Romosozumab at the Annual European Congress of Rheumatology (EULAR 2016) 79
May 31, 2016: Radius Announces FDA Acceptance for Filing of New Drug Application for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis 80
May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor 80
Apr 15, 2016: Radius Announces Three Oral Presentations for Abaloparatide-SC at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease 81
Apr 01, 2016: Radius Presents Analysis Results on Fracture Risk Reduction in Phase 3 ACTIVE Trial for Investigational Drug Abaloparatide-SC at the ENDO 2016 Annual Meeting 82
Apr 01, 2016: Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables

Number of Products under Development for Post Menopausal Osteoporosis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H2 2016 14
Post Menopausal Osteoporosis - Pipeline by BiologicsMD, Inc., H2 2016 15
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H2 2016 16
Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma, Inc., H2 2016 17
Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 18
Post Menopausal Osteoporosis - Pipeline by Ipsen S.A., H2 2016 19
Post Menopausal Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 20
Post Menopausal Osteoporosis - Pipeline by NIBEC, H2 2016 21
Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H2 2016 22
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Post Menopausal Osteoporosis - Dormant Projects, H2 2016 69
Post Menopausal Osteoporosis - Discontinued Products, H2 2016 70